Hispanics are the largest and fastest-growing minority population in the United States, currently comprising about 16.3% (52 million) of the total population. With an increased prevalence of metabolic risk factors in this population, the rate of uncontrolled hypertension (HTN) in Hispanics significantly exceeds the rates observed among nonHispanic blacks and whites. Unfortunately, data on HTN in Hispanics remains limited due to the under-representation of Hispanics in clinical trials; with most of the data primarily restricted to observational and retrospective subgroup analyses. This article aims to review the available data on prevalence, awareness and control of HTN, risk factors and some of the challenges unique to the Hispanics population. We also discuss treatment strategies derived from large HTN trials that included Hispanics.
Introduction
Hispanics, with an estimated population of 52 million, represent the largest minority group in the United States (US) and by 2050 are predicted to become the country's majority population with1 in 3 US residents being of Hispanic descent. (1) Epidemiological and population based data suggests that the rate of uncontrolled hypertension (HTN) in Hispanics significantly exceeds the rates observed among nonHispanic blacks and whites. (2) Approximately 29% of the adult US population carries the diagnosis of HTN (3) and with estimates suggesting that this number will continue to increase, HTN and its consequences will remain a major public health issue especially in Hispanics. In addition, Hispanics are more likely to be affected by obesity and type 2 diabetes (T2D) when compared to non-Hispanic whites. (4) The higher prevalence of these cardiovascular (CV) risk factors further contributes to the increase morbidity and mortality associated with HTN in this population. Unfortunately, data on HTN in Hispanics still remains limited due to their under-representation in clinical trials; with most of the data primarily restricted to observational and retrospective subgroup analyses.
This article aims to review the epidemiology and prevalence of HTN in Hispanics, clinical characteristics, treatment strategies and specific challenges such as lack of access to health care, low socioeconomic status, language barriers and degree of acculturation.
Demographics
Unlike other ethnic groups, Hispanics represent the only ethnic group defined not by geographic origin but rather by common language, (5, 6) which explains the heterogeneity and diversity of this group. In 2010 Mexican-Americans were by a large margin the most
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numerous Hispanic sub-group (63%), compared to Puerto-Ricans (9.2%), Cubans (3.5%), Salvadorans (3.3%) and Dominicans (2.8%), and the remaining 18.2% self-defined as other-Hispanic or Latino origin. According to the 2010 Census, 308.7 million people resided in the US of which 50.5 million (or 16 percent) were self-described Hispanic or
Latino. Additionally, more than half of the population growth in the US over the last decade was attributable to the increase in the Hispanic population. A C C E P T E D M A N U S C R I P T
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Obesity
Obesity, a major risk factor for HTN and CVD, continues to be a pervasive epidemic in the US. The prevalence of over-weight / obesity in the US has risen to a staggering 64% of children and 31% in adults. (13) However Hispanics are 20% more likely to be obese compared to non-Hispanic whites, the prevalence of obesity is even greater in MexicanAmerican women, who are 40% more likely to be obese compared with non-Hispanic white women. This disparity is even greater in children, with Mexican-American children having 60% increased risk of being overweight compared to non-Hispanic whites. (9) Within Hispanic sub-groups, there are subtle differences in the prevalence of obesity, (54, 55) where valsartan/HCTZ was more effective than valsartan alone in lowering BP among
Hispanics. (54, 55) In summary, the available data suggest that the rennin angiotensin aldosterone system antagonists agents alone or in combination with diuretics, seem to be an effective treatment strategy for Hispanics HTN patients.
Conclusions / Future Directions
As demonstrated by the limited data available from clinical trials, the pressing problem for the management of HTN in the Hispanic population is not finding adequate and effective therapy, but identifying HTN and providing access to care for the Hispanic population. The higher prevalence of uncontrolled HTN is directly related to lack of access to healthcare, which is partially due to lower socio-economic status, language barriers and education. With limited data on medication class effect on HTN control and CV outcomes in Hispanics, we cannot make treatment recommendations. However, as
shown previously, presence of comorbidities such as obesity, MetS, dyslipidemia (56) , and T2D in Hispanics may aid in the choice of a specific anti-HTN therapy.
While future clinical trials should endeavor to separate the heterogeneous Hispanic population into sub-groups, this may not be feasible for recruitment purposes. However, practitioners should keep in mind the differences in risk factor profiles among the Hispanic sub-groups when evaluating and treating HTN.
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Drug therapy cannot be the sole treatment strategy to deal with the inevitable increase in disease burden over the next decades. Efforts to improve patient education about the importance of physical activity and risk factor modification and access to regular medical care in the Hispanic population must be the cornerstone of any treatment strategy. As the Hispanic population continues to grow in the US, the health and wellbeing of this heterogeneous group of people will be ultimately reflected on the health of the nation. A C C E P T E D M A N U S C R I P T 
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